In the 2-week taper phase , participants received placebo , desvenlafaxine 50 mg/d then placebo ( 7 days each ) , desvenlafaxine 50 mg/d then 25 mg/d ( 7 days each ) , or desvenlafaxine 50 mg/d every other day .
